Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579187 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329512 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL7718097 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL8746346 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL5579185 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL4329518 | 1.00 | MEN1 (0.77) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718910 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL16718912 | 0.99 | MEN1 (0.76) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL10699234 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT | |
| SCHEMBL29926784 | 0.96 | MEN1 (0.84) | MEN1KMT2ALTB4R2ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035573-B1 | METHODS FOR IDENTIFYING MODULATORS OF EOXIN FORMATION | BIOLIPOX AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090247634-A1 | Methods for identifying modulators of eoxin formation | CLAESSON HANS-ERIK | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247634-A1 | Methods for identifying modulators of eoxin formation | LTA4H, LTC4S, LTB4R2 | MEN1 4604/4885KMT2A 3941/4885LTB4R2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.